DOD Glioblastoma, Hypothesis Development Award
ID: 356428Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356428
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    FY24.pdf
    The Fiscal Year 2024 Department of Defense Glioblastoma Research Program (GBMRP) outlines two primary award mechanisms: the Hypothesis Development Award and the Resource Development Award. Both awards target independent investigators at all career levels, emphasizing the encouragement of early-career researchers. The Hypothesis Development Award supports innovative, exploratory research addressing significant issues in glioblastoma, particularly in drug delivery and biomarkers. A Letter of Intent is mandatory before applying, and the funding caps are set at $200,000 for single principal investigators and $300,000 for partnering teams, with a performance period of up to two years. In contrast, the Resource Development Award focuses on enhancing preclinical model systems necessary for glioblastoma research. Applicants must provide preliminary data, with funding available up to $500,000 for direct costs and a maximum performance period of three years. Similar to the previous award, a Letter of Intent is required. Both awards exclude clinical trials but permit related clinical and animal research. The submission deadlines for both awards are November 6, 2024 (Letter of Intent) and November 20, 2024 (full application). This document serves as a vital resource for researchers seeking funding opportunities within the federal framework, reinforcing the government’s commitment to advancing glioblastoma research through well-structured grant mechanisms.
    HT942524GBMRPHDA.pdf
    The Department of Defense (DOD) is soliciting applications for the fiscal year 2024 Glioblastoma Hypothesis Development Award (HDA) under its Congressionally Directed Medical Research Programs (CDMRP). This program aims to fund innovative research that improves glioblastoma patient survival and reduces negative impacts on Service Members and the broader American public. Planning a two-step application process, the deadlines for submissions are set for November 6, 2024 (pre-application) and November 20, 2024 (full application). The total funding available is approximately $10 million, with awards supporting projects that address relevant experimental focus areas such as drug delivery and biomarker identification. Eligibility spans a wide range of organizations, including academic institutions and private entities. Applicants are encouraged to present groundbreaking concepts without the need for preliminary data, emphasizing significant potential impact. Specifics such as funding limits, submission protocols via eBRAP and Grants.gov, and review criteria guide the application process. The awards will facilitate exploration into glioblastoma, particularly the IDH-wild type forms, through rigorous scientific inquiry that directly benefits the affected communities and enhances medical research.
    Similar Opportunities
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Tactical Behaviors for Autonomous Maneuver
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R21 Clinical Trial Not Allowed), aimed at advancing research in the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between microorganisms, tumors, and the immune system, focusing on their potential to develop innovative strategies for cancer imaging and therapeutics, particularly for solid tumors and oral cancers. The program supports exploratory and developmental research with a maximum budget of $275,000 over two years, encouraging multidisciplinary collaboration to address significant challenges in cancer therapy. Applications are due by May 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Active
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Department of Army Energetics Basic Research Center (EBRC) Fiscal Year 2025
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army, through the Materiel Command, is offering a funding opportunity for the Energetics Basic Research Center (EBRC) for Fiscal Year 2025, aimed at advancing research in energetic materials (EM) critical to U.S. national security. This initiative invites eligible applicants, including universities, nonprofit organizations, state and local governments, and for-profit entities, to submit white papers and proposals that focus on innovative research in EMs, particularly in areas such as novel materials, microstructure influence, and advanced diagnostics. The program is designed to enhance the Army's capabilities in developing new materials and technologies that improve weapon systems' performance and effectiveness, with a total funding ceiling of $1 million anticipated for up to six awards ranging from $60,000 to $250,000 per year. Interested parties should submit white papers by January 6, 2025, and proposals by invitation by April 7, 2025; for further inquiries, contact Schon Zwakman at schon.m.zwakman.civ@army.mil or by phone at 919-541-4722.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (PAR-25-107). This initiative invites grant applications that explore the use of bacteria, archaebacteria, bacteriophages, and non-oncolytic viruses to investigate their interactions with tumors and the immune system, aiming to develop innovative strategies for cancer imaging and therapy, particularly for oral cancers. The program encourages multidisciplinary collaboration among experts in microbiology, cancer biology, and immunology to address challenges associated with solid tumors and metastases. Applications will be accepted starting January 5, 2025, with no budget limit, and the project period can extend up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory and developmental research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) through the R21 grant mechanism (Funding Opportunity Number: RFA-NS-25-025). The initiative aims to enhance understanding of the immunological mechanisms, genetic factors, and potential treatment strategies for these autoimmune neuropathies, with a focus on innovative research that could lead to significant advancements in diagnosis and treatment. Approximately $3 million is available to support up to seven research projects, each with a budget of up to $275,000 over a two-year period. Applications are due by October 4, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)" aimed at supporting small research projects that analyze genomic and phenotypic datasets related to childhood cancers and structural birth defects. This initiative is part of the Gabriella Miller Kids First Pediatric Research Program, which seeks to enhance understanding and treatment of pediatric conditions through collaborative genomic research by providing access to curated data resources. Eligible applicants include a wide range of organizations, such as educational institutions and nonprofits, with grants available up to $200,000 over a two-year period. Interested parties should note that the application deadline is November 16, 2025, and can find further details and submission guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.